

# EYLEA® (aflibercept) 8 mg real-world evidence

## 12-month real-world outcomes in patients with nAMD

York and Scarborough Teaching Hospitals NHS Foundation Trust

### nAMD

These data are from real patients. Individual results may vary.

#### Study design:

Retrospective study evaluated outcomes in 59 treatment-naïve eyes and 142 previously treated eyes with nAMD.

Patients with nAMD were treated with the aim of completely removing fluid following the loading phase. Patients not achieving  $\geq$ q8 treatment intervals following the loading phase switched treatment from EYLEA 8 mg.


#### Patient demographics in treatment-naïve patients

Eyes, N	59
Mean age, years	83
Female, %	58

### Treatment-naïve patients

## Fast and sustained drying from three loading doses of EYLEA 8 mg to 12 Months

#### Change in CRT over time



After loading:  
**-99 µm**

Month 12:  
**-116 µm**

Mean change in CRT from baseline with EYLEA 8 mg

## Interval extension with EYLEA 8 mg




Mean (SD) treatment interval of  
**10.9 (2.1) weeks**  
between injections of EYLEA 8 mg at 12 months



## Meaningful vision gains with EYLEA 8 mg

#### Change in VA over time



After loading:  
**+6.0 ETDRS letters**

Month 12:  
**+5.8 ETDRS letters**

Mean change in VA from baseline with EYLEA 8 mg

\*N numbers are variable as some eyes are missing data or may have been moved to another treatment. Differing numbers are from different patients. Patients not achieving  $\geq$ q8 treatment interval following the loading phase switched treatment from EYLEA 8 mg.

#### Abbreviations:

CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; nAMD, neovascular age-related macular degeneration; qX, every X weeks; SD, standard deviation; VA, visual acuity.

#### Reference:

Bayer UK Data on File\_PP-EYL\_8mg-GB-0905\_January

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right. Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.



**nAMD**

**Previously treated patients**

**Patient demographics in previously treated patients**

Eyes, N	142
Mean age, years	83
Female, %	66




**35**

Mean number of injections prior to switch


**Extended treatment intervals with EYLEA 8 mg vs. previous anti-VEGFs**

**Last completed treatment interval**



**Maintained fluid control with EYLEA 8 mg**

**Change in CRT over time**




**After loading: -4.0 µm**

**Month 12: -29.0 µm**

Mean change in CRT from baseline with EYLEA 8 mg

**Maintained vision with EYLEA 8 mg**

**Change in VA over time**



**After loading: +0.0 ETDRS letters**

**Month 12: -0.7 ETDRS letters**

Mean change in VA from baseline with EYLEA 8 mg

The safety profile of EYLEA 8 mg was consistent with that in published studies such as PULSAR and PHOTON. No new adverse events were reported.

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile. \*N numbers are variable as some eyes are missing data or may have been moved to another treatment. Differing numbers are from different patients. Patients not achieving ≥q8 treatment interval following the loading phase switched treatment from EYLEA 8 mg.

**Abbreviations:**  
**CRT**, central retinal thickness; **ETDRS**, Early Treatment Diabetic Retinopathy Study;  
**nAMD**, neovascular age-related macular degeneration; **qx**, every X weeks;  
**VA**, visual acuity; **VEGF**, vascular endothelial growth factor.

**Reference:**  
 Bayer UK Data on File\_PP-EYL\_8mg-GB-0905\_January

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right. Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

